Literature DB >> 26132594

Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.

Jose M Torregrosa1, Francisca Ferrer-Marín2, María L Lozano1, Maria J Moreno1, Constantino Martinez1, Ana I Anton1, José Rivera1, Vicente Vicente1.   

Abstract

Entities:  

Keywords:  essential thrombocythaemia; leucocytes; mutations; platelet activation; thrombosis

Mesh：

Substances：

Year:  2015        PMID： 26132594     DOI： 10.1111/bjh.13539

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

Review 1.  Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.

Authors:  L Falchi; H M Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2017-05-22       Impact factor: 11.528

2.  Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Authors:  Alberto Alvarez-Larrán; Arturo Pereira; Paola Guglielmelli; Juan Carlos Hernández-Boluda; Eduardo Arellano-Rodrigo; Francisca Ferrer-Marín; Alimam Samah; Martin Griesshammer; Ana Kerguelen; Bjorn Andreasson; Carmen Burgaleta; Jiri Schwarz; Valentín García-Gutiérrez; Rosa Ayala; Pere Barba; María Teresa Gómez-Casares; Chiara Paoli; Beatrice Drexler; Sonja Zweegman; Mary F McMullin; Jan Samuelsson; Claire Harrison; Francisco Cervantes; Alessandro M Vannucchi; Carlos Besses
Journal:  Haematologica       Date:  2016-05-12       Impact factor: 9.941

Review 3.  Essential thrombocythemia: a hemostatic view of thrombogenic risk factors and prognosis.

Authors:  Mohsen Maleknia; Saeid Shahrabi; Majid Ghanavat; Tina Vosoughi; Najmaldin Saki
Journal:  Mol Biol Rep       Date:  2020-05-30       Impact factor: 2.316

Review 4.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

5.  [Clinical features and risk factors of vein thrombosis in 259 patients with chronic myelofiberation neoplasms].

Authors:  M J Huang; Z P He; H Y Tian; Y Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-07-14

Review 6.  Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms.

Authors:  Cecilia P Marin Oyarzún; Paula G Heller
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

Review 7.  Mutant Calreticulin in the Myeloproliferative Neoplasms.

Authors:  Daniel Prins; Carlos González Arias; Thorsten Klampfl; Jacob Grinfeld; Anthony R Green
Journal:  Hemasphere       Date:  2020-01-15

Review 8.  Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms.

Authors:  Francisca Ferrer-Marín; Ernesto José Cuenca-Zamora; Pedro Jesús Guijarro-Carrillo; Raúl Teruel-Montoya
Journal:  Int J Mol Sci       Date:  2021-01-24       Impact factor: 5.923

9.  CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Authors:  Roberta Zini; Paola Guglielmelli; Daniela Pietra; Elisa Rumi; Chiara Rossi; Sebastiano Rontauroli; Elena Genovese; Tiziana Fanelli; Laura Calabresi; Elisa Bianchi; Simona Salati; Mario Cazzola; Enrico Tagliafico; Alessandro M Vannucchi; Rossella Manfredini
Journal:  Blood Cancer J       Date:  2017-12-08       Impact factor: 11.037
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.